Category 5 - DIAGNOSTIC IMAGING SERVICES
61530 - Additional Information
Item Start Date:
01-Nov-2025
Description Updated:
01-Nov-2025
Schedule Fee Updated:
01-Nov-2025
Group
I4 - Nuclear Medicine Imaging
Subgroup
2 - PET
Whole body 68Ga-DOTA-somatostatin receptor agonist PET study for:
a) staging of histologically confirmed neuroendocrine neoplasm (NEN) considered surgically incurable on conventional imaging, or
b) evaluation of somatostatin receptor expression of histologically confirmed and inoperable NEN, either locally advanced or metastatic, under consideration for peptide receptor radionuclide therapy (PRRT); or
c) evaluation of response to PRRT therapy; or
d) evaluation of suspected recurrent or metastatic disease in known somatostatin receptor positive NEN.
(R)
(Anaes.)
Fee: $953.00 Benefit: 75% = $714.75 85% = $848.50
Legend
- Assist - Addition/Deletion of (Assist.)
- Amend - Amended Description
- Anaes - Anaesthetic Values Amended
- Emsn - EMSN Change
- Fee - Fee Amended
- Renum - Item Number Change (renumbered)
- New - New Item
- NewMin - New Item (previous Ministerial Determination)
- Qfe - QFE Change